Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 33, Issue 3, 2012, Pages 268-274

  Caglar, Meltem ^a   Bozkurt, Fani M ^a   Akca, Ceren Kapulu ^a   Vargol, Sezen Elhan ^a   Bayraktar, Miyase ^a   Ugur, Omer ^a   Karaaǧaoǧlu, Ergun ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

iodine 131; radioiodine ablation; thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADULT; AGED; ARTICLE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POORLY DIFFERENTIATED THYROID CANCER; POSTOPERATIVE PERIOD; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR ABLATION; ULTRASOUND; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NECK; PROSPECTIVE STUDIES; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84856089695     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834ec5d6     Document Type: Article

References (37)

1. DeGroot LJ, Kaplan EL, McCormick M, Strauss FH. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-424.
2. Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary anf follicular thyroid cancer. Am J Med 1994; 97: 418-428. (Pubitemid 24345593)
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306. (Pubitemid 28065257)
4. Wong JB, Kalpan MM, Meyer KB, Paukar SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19: 741-760. (Pubitemid 20282665)
5. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52: 763-773.
6. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987; 12: 500-502. (Pubitemid 17004386)
7. Johansen K, Woodhouse NJ, Odegbesan O. Comparison of 1073MBq and 3700MBq iodine-131 in the postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32: 252-254.
8. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 506 patients. J Clin Endocrinol Metab 2004; 89: 1666-1673. (Pubitemid 38507919)
9. Sobin L, Hand Wittekind CH. UICC TNM classification of malignant tumours. 6th ed. New York: Wiley Liss; 2002.
10. Miccoli P, Minuto MN, Orlandini C, Galleri D, Massi M, Berti P, et al. Ultrasonography estimated thyroid volume: a prospective study about its reliability. Thyroid 2006; 16: 37-39. (Pubitemid 43346501)
11. Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissmann HS, editors. Nuclear medicine annual. New York: Raven Press; 1983. pp. 329-383.
12. Synder J, Gorman C, Scanlon P. Thyroid remnant ablation: questionable pursuit of an ill defined goal. J Nucl Med 1983; 24: 659-665. (Pubitemid 13016085)
13. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Nucl Med 2006; 154: 787-803. (Pubitemid 43997716)
14. Bierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of 'ablation of thyroid remnants' with I-131 in 511 patients from 1947-1984: experiences at University of Michigan. J Nucl Med 1984; 25: 1284-1293.
15. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 96: 1447-1463. (Pubitemid 32374886)
16. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52: 765-773. (Pubitemid 30409270)
17. Leung SF, Law MW, Ho SK. Efficacy of low-dose iodine-131 ablation of postoperative thyroid remnants: a study of 69 cases. Br J Radiol 1992; 65: 905-909.
18. Van Wyngaarden M, McDougal IR. What is the role 1100 MBQ radioiodine I-131 in the treatment of patients with differentiated thyroid cancer? Nucl Med Commun 1996; 17: 199-207.
19. DeGroot LJ, Reilly M. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982; 96: 51-53. (Pubitemid 12205516)
20. Hodgson DC, Brierly JD, Tsang RW, Panzarella T. Prescribing I-131 iodine based on neck uptake produces effective thyroid ablation and reduced hospiatl stay. Radiother Oncol 1998; 47: 325-330. (Pubitemid 28293656)
21. Zidan J, Hefer E, Iosilevski G, Drumea K, Stein ME, Kuten A, et al. Efficacy of I-131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer. Int J Radiat Oncol Biol Phys 2004; 59: 1330-1336. (Pubitemid 38954054)
22. Lin JD, Kao PF, Chao TC. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 1998; 71: 307-313.
23. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic I-131 iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-1501. (Pubitemid 34615228)
24. Pacini F, Molinero E, Castanga MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3668-3673. (Pubitemid 37034512)
25. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient by itself, to monitor for residual thyroid caecinoma? J Clin Endocrinol Metab 2002; 87: 3242-3247. (Pubitemid 34816372)
26. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto L, Di Giorgio A, Modoni S, et al. Serum thyroglobulin and I-131 whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148: 19-24. (Pubitemid 36176000)
27. Robbins RJ, Schlumberger MJ. The evolving role of I-131 for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005; 46: 28S-37S. (Pubitemid 47619016)
28. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JWA, Franco FS, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004; 151: 539-548. (Pubitemid 39562507)
29. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine I-131 therapy for well differentiated thyroid cancer a quantitative radiation-dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132-1136.
30. Samuel AM, Rajashekharrao B. Radioiodine therapy for well differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid after surgery. J Nucl Med 1994; 3335: 1944-1950. (Pubitemid 24376609)
31. Maxon HR, Thomas SR, Hertzberg VS, Kereikes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937-941. (Pubitemid 13008961)
32. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997; 7: 183-187. (Pubitemid 27190577)
33. Hadjieva T. Quantitative approach to radioiodine ablation of thyroid remnants following surgery for thyroid cancer. Radiobiol Radiother 1985; 26: 819-823. (Pubitemid 16190620)
34. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13: 277-279. (Pubitemid 16015842)
35. Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 276-283.
36. Mallick U, Harmer C, Hackshaw A. The Hilo trial: a multicentre randomized trial of high versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol 2008; 20: 325-326. (Pubitemid 351636017)
37. Medico-economic comparison of four strategies of radioiodine ablation in thyroid carcinoma patients (Estimbl) [Internet]. Available at http: //clinicaltrials.gov/archieve/NCT00435851 [Accessed 16 October 2009].